跳至主要内容
临床试验/ISRCTN98848959
ISRCTN98848959进行中(未招募)未知

Metabolomic profiles in blood and urine as predictors of response to immunotherapy in lung cancer patients

Instituto de Salud Carlos III0 个研究点目标入组 131 人开始时间: 2020年7月17日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
131

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • Patients older than 18 years with stage III and IV NSCLC candidates for immunotherapy treatment

排除标准

  • 1. Patients with another primary malignancy diagnosed in the previous 5 years (except for cervical carcinoma in situ and non-melanoma skin cancer)
  • 2. Patients with tumours expressing actionable mutations in EGFR, ALK or ROS1
  • 3. Patients with stage IV severe kidney disease (creatinine clearance < 30 ml/min)
  • 4. Patients with severe liver disease (hepatitis, cirrhosis)
  • 5. Patients with low Performance Status (ECOG 3-4)
  • 6. Patients who refuse to sign the informed consent
  • 7. Any previous systemic immunotherapeutic treatment will also make the patient ineligible for the study

研究者

发起方
Instituto de Salud Carlos III

相似试验